Earnings ·
AVITA Medical reported second quarter 2026 net revenue of $21.7 million, an 18% year-over-year increase and a record…
RCELAVITA Medical, Inc.
AVITA Medical reported second quarter 2026 net revenue of $21.7 million, an 18% year-over-year increase and a record high, driven by RECELL sales of $18.5 million. The company raised its full-year 2026 revenue guidance to $86–$89 million from the previous range of $80–$85 million and expects to reach cash flow breakeven in the fourth quarter of 2026. Operating expenses decreased 6% year-over-year to $24.6 million, while net loss narrowed to $7.7 million ($0.25 per share) from $9.9 million in the prior-year period. The Centers for Medicare & Medicaid Services proposed national physician payment rates and increased facility payments for RECELL effective January 1, 2027. AVITA Medical operates in the therapeutic acute wound care industry, developing and commercializing solutions such as RECELL spray-on skin technology.